Is IVERIC bio, Inc. (ISEE) a Buy, Sell, or Hold?
NASDAQ : ISEE
IVERIC bio, Inc.
$39.95 USD
$0.15 (0.38%)
- Volume
- 10.8M
- Average Volume
- 5.29M
- Market Capitalization
- $5.51B
- P/E Ratio
- -27.55
- Dividend Yield
- 0.00%
- Price Target
- $34.50
- Year High
- $39.99
- Year Low
- $9.39
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $18.63
Company Overview
NASDAQ
Glenn P. Sblendorio
Biotechnology
Healthcare
ISEE
163
US
USD
Liquidity Metrics
0.18
18.63
18.63
13.38
0.00
Sales & Valuation
-$
0.00
9.04
-33.51
-1.36
Profitability
-$1.45
-$175.74M
0.00%
0.00%
-39.26%
-26.36%
P/E Metrics
-27.55
0.71
0.71
Analyst Price Target & Rating
$34.50
$35.00
$27.00
0/5
24 Analysts
15.80%
Poll Results
About IVERIC bio, Inc. (NASDAQ:ISEE) Stock
IVERIC bio, Inc. is a biopharmaceutical enterprise focused on identifying and advancing innovative therapeutic solutions for eye conditions, with a particular emphasis on age-related and rare inherited retinal diseases (IRDs). A cornerstone of its development pipeline is Zimura, an inhibitor targeting complement factor C5. This compound is currently undergoing investigation for geographic atrophy (GA), a severe form of dry age-related macular degeneration (AMD). Zimura's clinical progression includes the GATHER1 trial, which has successfully concluded its Phase 2/3 stage, and the GATHER2 trial, which is presently in Phase 3. The company's portfolio also features STAR (identified as OPH2005), a candidate in Phase 2b clinical trials for addressing Leber congenital amaurosis type 10 (LCA10) a ... nd autosomal recessive Stargardt disease (STGD1). Additionally, IVERIC bio is developing IC-500, a high-temperature requirement A serine peptidase 1 protein inhibitor intended for GA and other forms of age-related retinal degeneration. Other programs include IC-100, aimed at rhodopsin-mediated autosomal dominant retinitis pigmentosa, and IC-200, designed for IRDs stemming from mutations in the BEST1 gene. Beyond these active programs, the company has completed several earlier clinical trials: OPH2001, a Phase 1/2a study evaluating various doses of Zimura monotherapy for GA; OPH2000, a Phase 1/2a trial assessing different doses of Zimura combined with Lucentis for wet AMD; OPH2007, which concluded its Phase 2a study for wet AMD; and OPH2002, a Phase 2a trial for idiopathic polypoidal choroidal vasculopathy. In its earlier-stage research and discovery efforts, IVERIC bio is exploring programs such as miniCEP290 for LCA10, miniABCA4 for STGD1, and miniUSH2A for Usher syndrome type 2A-related IRDs. Established in 2007, the company, originally known as Ophthotech Corporation, adopted its current name, IVERIC bio, Inc., in April 2019. Its operations are based in Parsippany, New Jersey.
Frequently Asked Questions
-
What is the current IVERIC bio, Inc. (ISEE) stock price?
-
IVERIC bio, Inc.(NASDAQ:ISEE) stock price is $39.95 in the last trading session. During the trading session, ISEE stock reached the peak price of $39.99 while $9.39 was the lowest point it dropped to. The percentage change in ISEE stock occurred in the recent session was 0.38% while the dollar amount for the price change in ISEE stock was $0.15.
-
ISEE's industry and sector of operation?
-
The NASDAQ listed ISEE is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ISEE?
-
Amy R. Sheehan | Senior Vice President & Chief HR Officer
Todd Anderman | Senior Vice President, Chief Legal Officer & Corporation Sec.
|
|
| -
How many employees does ISEE have?
-
Number of ISEE employees currently stands at 163. ISEE operates from 8 Sylvan Way, Parsippany, NJ 07054, US.
-
Link for ISEE official website?
-
Official Website of ISEE is: https://ivericbio.com
-
How do I contact ISEE?
-
ISEE could be contacted at phone #609 474 6755 and can also be accessed through its website. ISEE operates from 8 Sylvan Way, Parsippany, NJ 07054, US.
-
How many shares of ISEE are traded daily?
-
The average number of ISEE shares traded daily for last 3 months was 5.29M.
-
What is the market cap of ISEE currently?
-
The market value of ISEE currently stands at $5.51B with its latest stock price at $39.95